Amphastar Pharmaceuticals Inc (AMPH) financials

NASDAQ · Health Care

$27.72 +2.93% Close Oct 30, 2026 Live

Amphastar Pharmaceuticals revenue and earnings by year

Amphastar Pharmaceuticals's revenue was $720 million in the fiscal year to December 31, 2025, down 1.7% from the year before. Net income was $98.1 million, 13.6% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 12.2% a year on average.

RevenueNet income
$0$250M$500M$750M
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Revenue720732644499438350322295240255
Revenue growth-1.7%13.6%29.1%14.0%25.1%8.5%9.4%22.7%-5.9%—
Gross profit35637435124920014313210791104
Gross margin49.5%51.1%54.5%49.9%45.6%41.0%40.9%36.3%37.7%40.8%
Operating income1402051971077011-0-9-115
Operating margin19.5%28.1%30.6%21.5%16.0%3.1%-0.0%-2.9%-0.5%6.0%
Net income981601389162149-6410
Net margin13.6%21.8%21.3%18.3%14.2%0.4%15.2%-1.9%1.5%3.8%
Diluted EPS$2.03$3.06$2.60$1.74$1.25$0.03$0.99-$0.12$0.08$0.22
Free cash flow1211721456671230-8417

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open AMPH in Markets.

See also: AMPH valuation and P/E history · AMPH returns

No forecast, no recommendation. This page describes Amphastar Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.